Project Grant R15HL188529
Award Date 8/1/26
Completion Date 4/30/29
Dollars Obligated $594K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lubbock, TX 79409, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $143,461 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct high-resolution phenotyping of hemodynamic consequences in adults who have undergone thoracic endovascular aortic repair (TEVAR) for descending thoracic aortic aneurysm. The research assesses how graft material stiffness following TEVAR affects pressure, wave reflections, and pulsatility in...
- The National Heart, Lung, and Blood Institute awarded East Tennessee State University $536,447 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to investigate mechanisms of macrophage retention in the extracellular matrix during atherosclerosis development. The project examines how oxidation of polyunsaturated fatty acids—including docosahexaenoic acid, arachidonic acid, and linolenic acid—generates adhesive substrates in vascular tissue that anchor...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $697,198 to the University of Texas at Austin on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-biased integrin-mediated endothelialization processes for precision vascular graft design. The recipient is conducting research to identify how biological sex affects endothelial cell behavior in response...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center $718,548 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endothelial FLI1 in ischemic heart disease. The funded research examines how Friend Leukemia Integration 1 (FLI1), a transcription factor, governs endothelial cell function and protects against myocardial damage under ischemic stress. Preliminary data using...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $608,173 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the stretch-activated PIEZO1 channel in heart failure-associated atrial fibrillation. The research comprises three aims: testing the hypothesis that atrial stretch-induced PIEZO1 activation contributes to pathological atrial remodeling and atrial fibrillation predisposition...
- The National Heart Lung and Blood Institute awarded The University of Texas Southwestern Medical Center $662,275 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate ether lipid salvage mechanisms through the ACAD10 enzyme. The research examines how mammalian ACAD10 and its paralog ACAD11 regulate the salvage of dietary ether lipids—specialized membrane lipids that constitute up to 20 percent of the phospholipid pool in eukaryotic cells and play...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025 through July 31, 2027. The research will investigate the force transduction mechanisms of leukocyte function-associated antigen-1 (LFA-1), a critical CD18 integrin that mediates immune cell adhesion, migration, and...
- The National Heart, Lung, and Blood Institute awarded Yale University $126,177 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund postdoctoral and early-career research investigating the role of intraflagellar transport protein IFT88 in smooth muscle cell phenotype and vascular remodeling. The research addresses mechanisms by which smooth muscle cells in blood vessel walls transition between differentiated and dedifferentiated phenotypes—a process...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $248,679 on February 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the nuclear protein HMGXB4 in occlusive vascular diseases. The research examines vascular smooth muscle cell phenotypic modulation in restenosis and atherosclerosis. The project focuses on elucidating how HMGXB4 regulates the transition from contractile to...